絞り込み

17908

広告

Targeting DNA methylation for treating triple-negative breast cancer.

著者 Yu J , Zayas J , Qin B , Wang L
Pharmacogenomics.2019 Nov ; 20(16):1151-1157.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (14view , 0users)

Full Text Sources

Medical

Miscellaneous

Research Materials

Triple-negative breast cancer (TNBC) accounts for 15-20% of all invasive breast cancers and tends to have aggressive histological features and poor clinical outcomes. Unlike, estrogen receptor- or HER2-positive diseases, TNBC patients currently lack the US FDA-approved targeted therapies. DNA methylation is a critical mechanism of epigenetic modification. It is well known that aberrant DNA methylation contributes to the malignant transformation of cells by silencing critical tumor suppressor genes. DNA methyltransferase inhibitors reactivate silenced tumor suppressor genes and result in tumor growth arrest, with therapeutic effects observed in patients with hematologic malignancies. The antitumor effect of these DNA methyltransferase inhibitors has also been explored in solid tumors, especially in TNBC that currently lacks targeted therapies.
PMID: 31755366 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード